Orrick Advises Oisín Biotechnologies on Financing


Orrick has advised Seattle-based biotechnology company Oisín Biotechnologies on its $3 million pre-seed SAFE funding round. Oisín is developing therapeutics to identify and kill senescent cells to reduce the effects of the aging process. The company was recently recognized in MIT Technology Review’s TR10, which highlights the top 10 breakthrough technologies of 2020.

Orrick previously advised OncoSenX, a spinout of Oisín Biotechnologies, on its $3 million pre-seed funding raise. OncoSenX is developing therapeutics to kill cancer cells based on their genetics.

The Orrick team advising on these financings include Blake Ilstrup, Laura Bloxham and Brigid McCurdy.